Abstract:The majority of clinical degrader candidates utilize an immunomodulatory imide drug (IMiD)-based derivative, that directs their target substrate to the E3 ligase receptor Cereblon (CRBN), however, concomitant neo-substrate degradation by IMiDs often results in severe off-target effects. Further biophysical screening is needed to discover CRBN binders that might overcome these safety concerns, but the previously reported CRBN protein constructs suffer significant limitations that reduce their applicability as tools for biophysical assays making large-scale screening efforts a costly endeavor. This is due to the requirement of CRBN co-expression with DDB1 in insect cells to produce soluble protein that contains all the reported structural features necessary for proper compound interaction. Here, a near full-length human CRBN construct was designed that retains these required features, but for the first time allows the generation of highly homogenous and cost-efficient expression in , eliminating the need for DDB1 co-expression. We have extensively profiled the new construct against the existing CRBN constructs in binary and ternary degrader complexes, showing it to be the “best of both worlds” in terms of binding characteristics and ease of protein production. We then designed the Enamine CRBN focused IMiD library of 4480-compounds and demonstrated applicability of the new construct to high throughput screening by identifying novel CRBN binders with high potency and ligand efficiency. The new methods described here should serve as valuable tools for the development of the next generation IMiD-based degraders.

Engineering CRBN for rapid identification of next generation binders

Design of a Cereblon construct for crystallographic and biophysical studies of protein degraders

Discovery of CRBN-dependent WEE1 Molecular Glue Degraders from a Multicomponent Combinatorial Library

The cyclimids: Degron-inspired cereblon binders for targeted protein degradation

An in-cell approach to evaluate E3 ligases for use in targeted protein degradation.

Cereblon Modulators Target ZBTB16 and Its Oncogenic Fusion Partners for Degradation Via Distinct Structural Degrons.

Unbiased mapping of cereblon neosubstrate landscape by high-throughput proteomics

Identification of Potent, Selective, and Orally Bioavailable Small-Molecule GSPT1/2 Degraders from a Focused Library of Cereblon Modulators

Discovery of electrophilic degraders that exploit SNAr chemistry

A Degron Blocking Strategy Towards Improved CRL4CRBN Recruiting PROTAC Selectivity

Discovery and Characterization of a Novel Cereblon-Recruiting PRC1 Bridged PROTAC Degrader

Crbn-based molecular Glues: Breakthroughs and perspectives

Mining the CRBN Target Space Redefines Rules for Molecular Glue-induced Neosubstrate Recognition

Structure-Based Design of CBP/EP300 Degraders: When Cooperativity Overcomes Affinity

The E3 ligase adapter cereblon targets the C-terminal cyclic imide degron

Discovery of potential novel CRBN modulators by virtual screening and bioassay

Selective CK1α degraders exert antiproliferative activity against a broad range of human cancer cell lines

Discovery of Novel Potential CRBN Modulators Through Structure-Based Virtual Screening and Bioassay

Structure-based Design of CBP/EP300 Degraders: When Coopera-tivity Overcomes Affinity

Unveiling the hidden interactome of CRBN molecular glues with chemoproteomics

Covalent Ligand Screening Uncovers a RNF4 E3 Ligase Recruiter for Targeted Protein Degradation Applications